Oncogenic proteomics is a powerful tool for studying the proteome-level alterations associated with HIV-associated malignancies. This section provides an overview of proteomics technologies, including mass spectrometry-based approaches, and their applications in cancer research. Proteomic profiling studies have identified dysregulated proteins and signalling pathways associated with HIV-associated malignancies. This section discusses key findings from proteomic studies focused on Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer, shedding light on the underlying molecular mechanisms and potential therapeutic targets [6]. Immunotherapeutic approaches, such as immune checkpoint inhibitors, have shown promise in the treatment of certain HIV-associated malignancies. This section explores the role of proteomics in identifying immunotherapeutic targets and discusses the potential for personalized medicine approaches.